The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment - Concepedia

Concepedia

Publication | Open Access

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

DOI Full Paper Access

203

Citations

27

References

2020

Year

Éric Rondeau, Marie Scully, Gema Ariceta, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, Stephan Ortiz, Eugene Swenson, Marc Vallée, Sung‐Soo Yoon,

Kidney International

References

	Year	Citations

Page 1